Tissue agnostic treatments can be used to target known cancer mutations, independent of cancer type. Here, the authors identified tissue-agnostic biomarkers in 21.5% of patients in a cohort of 295,316 tumor samples, and observed variable clinical benefit of tissue-agnostic treatments across cancer types.
- George W. Sledge Jr.
- Takayuki Yoshino
- David Spetzler
